The Anthropic IPO is live.
After weeks of holding our breath and playing will-they-won’t-they, Anthropic set its proposed deal size, valuation, and timing. For a deal this large, bankers typically leave room to price above the midpoint.
Here’s the current tearsheet:
Terms: 825 million shares at a range of $70 to $78. Shares are 97% primary.
Deal size: $61 billion at $74 midpoint. A high-end pricing, greenshoe, and $26B private placement could put the total raise above $100 billion.
Valuation: $1.2 trillion market cap at midpoint.
Timing: Pricing Wed. Nov. 18, trading Thu. Nov. 19.
Financials: $17B in Q3 revenue, 15% adj. EBITDA margin
Roadshow: See it here through Wednesday. Plus Dario Amodei’s fireside chat with Jamie Dimon. Some of his points on AI and exponential growth also appear in my upcoming book.
Amodei repeated his promise to “under-promise and overdeliver” for investors. Don’t think too hard about that one!
He also addressed key investor concerns. He argued that Anthropic’s nearly $900 billion in compute commitments could actually fall short of expected demand, pointed to Haiku as an answer to lower-cost competitors, and highlighted growth opportunities in pharma and cybersecurity. The company also launched its own spreadsheet tool this week.
More concrete was the latest S-1/A’s $81 billion annualized revenue run rate in October, easing concerns about slowing growth in Q3. Less clear is how much sales and marketing spend it took to get there. (Our IT team certainly appreciates all the free tokens.)
I’m inclined to ignore the elephant in the room. The turmoil surrounding Jensen Huang is a reminder that with expectations for AI so high, virtually any news story can send the sector sharply higher or lower. The headlines will pass, but Anthropic’s IPO is a seminal event in capital markets.
This week’s IPOs: Biotech continued its hot streak as asthma-focused Windward Bio (Nasdaq: WWB) soared +68% in its debut. Fast-growing cavity treatment provider vVardis (NYSE: VVVV) broke issue. Rezera showed that biotechs aren’t getting a blank check, postponing its deal.
One company filed, but it was a big one: American Barrick Gold (NYSE: ABGC) could raise over $5 billion in December. Parent Barrick Mining is hoping that a pure-play carve-out of its gold assets will unlock value. Several filers refreshed their filings with Q3 numbers, betting that Anthropic can reopen the IPO window. The list included neocloud Nscale, power equipment supplier Aggreko, and beauty brand owner Wella.
The IPO Index rebounded +3.4% this week, ahead of the S&P 500’s +2.5% gain. The AI infrastructure trade dominated the winners, led by next-gen geothermal producer Fervo Energy, up +27.5%. The prior week’s winner, electric aircraft maker BETA Technologies, gave up some of its gains, off -14.0%.
Take care,
Bill Smith
CEO and Founder
Renaissance Capital
Weekly US IPO Winners & Losers
| Company | Ticker | Return |
|---|---|---|
| Fervo Energy | FRVO | 27.5% |
| Legence | LGN | 25.4% |
| Cerebras Systems | CBRS | 21.2% |
| Astera Labs | ALAB | 16.3% |
| CoreWeave | CRWV | 14.5% |
| Company | Ticker | Return |
|---|---|---|
| BETA Technologies | BETA | -14.0% |
| Karman Holdings | KRMN | -10.9% |
| Lineage | LINE | -9.8% |
| Caris Life Sciences | CAI | -8.7% |
| Circle Internet Group | CRCL | -8.4% |
| Sector | Return |
|---|---|
| Utilities | 27.5% |
| Energy | 13.2% |
| Technology | 4.8% |
| Financials | 4.0% |
| Industrials | 3.9% |
| Consumer Staples | -0.6% |
| Consumer Discretionary | -0.7% |
| Health Care | -2.7% |
| Real Estate | -3.5% |
Renaissance IPO ETF (NYSE symbol: IPO) tracks the Renaissance IPO Index
The Renaissance IPO Index returned 3.4% last week vs. 2.5% for the S&P 500.

